There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Trillium Therapeutics
Tag: TRIL
The Chief Scientific Officer of Trillium Therapeutics is Exercising Options
Today it was reported that the Chief Scientific Officer of Trillium Therapeutics (TRIL – Research Report), Robert Uger, exercised options
The Chief Financial Officer of Trillium Therapeutics is Exercising Options
Today it was reported that the Chief Financial Officer of Trillium Therapeutics (TRIL – Research Report), James Todd Parsons, exercised
The Chief Development Officer of Trillium Therapeutics is Exercising Options
Today it was reported that the Chief Development Officer of Trillium Therapeutics (TRIL – Research Report), Penka Petrova, exercised options
Trillium Therapeutics (TRIL) was Upgraded to a Buy Rating at Bloom Burton
Trillium Therapeutics (TRIL – Research Report) received a Buy rating and a $20.00 price target from Bloom Burton analyst David
Trillium Therapeutics (TRIL) Got Some Good News
H.C. Wainwright analyst Swayampakula Ramakanth upgraded Trillium Therapeutics (TRIL – Research Report) to Buy today and set a price target
JonesTrading Believes Trillium Therapeutics (NASDAQ: TRIL) Won’t Stop Here
In a report released yesterday, Soumit Roy from JonesTrading reiterated a Buy rating on Trillium Therapeutics (TRIL – Research Report),